

TABLE OF CONTENTS

INSTRUCTIONS FOR USE	10
Background.....	10
Rationale	11
Organization.....	12
Use of Lecture Modules.....	13
Consultation	14
Acknowledgements.....	15
Related Articles.....	16
CONTRIBUTORS	17

VOLUME I: A CURRICULUM & TEACHING MATERIALS

PART I: INTRODUCTION TO THE ASCP'S MODEL CURRICULUM

PREFACE.....	24
Using the Model Curriculum to Teach Medical Students, Primary Care Physicians and Other Mental Health Professionals	26
RATIONALE.....	27
ORGANIZATION OF A PSYCHOPHARMACOLOGY PROGRAM.....	27
Relationship of Research to Training	28

PART II: THE CORE CURRICULUM

OVERVIEW AND EDUCATIONAL OBJECTIVES	29
Knowledge.....	29
Skills	30
WHAT AND HOW TO TEACH.....	34
The Didactic Program.....	34
Organization of Courses and Lectures.....	34
Special Considerations Related to Lectures.....	35
• Issues, Concepts and a Template.....	37
• Specific Lecture Topics.....	41
• Lectures on Psychosocial Topics.....	48

Literature Review Seminar	50
Case Conference	53
Computers and Psychopharmacology	54
• General	55
• Research	55
• Journals.....	55
• Organizations.....	56
• Personal Digital Assistants (PDAs).....	56
• Other Teaching Tools	57
Supervision	57
• Introduction	57
• Background.....	58
• Rationale.....	58
• Use of Clinical Mentorship Teaching Using Selected Case Material.....	62
• Supervision in Drug Clinics, Inpatient Units and Emergency Rooms	63
An Alternative Approach to Psychopharmacology Teaching	64
• Description	64
• Goals.....	65
• Critique	66
• Reference.....	66
Off-Label Prescribing	66
Reading Materials	67
• Textbooks	67
• Journals and Newsletters	67
Neuroscience Lecture Series.....	70
Psychopharmacology Units	71
HOW TO EVALUATE	73
Formal Examination.....	73
Charting Patterns.....	74
Supervisor Evaluation.....	76

Trainee Evaluation of Supervision and of the Program.....	77
Accreditation Issues.....	77
Relevant Websites.....	77
FINAL PEARLS.....	78
Professionalism.....	78
Words of Wisdom.....	78

PART III: CURRICULUM FOR SPECIAL AREAS

CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY.....	80
Child and Adolescent Lecture Series.....	81
Child and Adolescent Instruments and Rating Scales.....	83
GERIATRIC PSYCHOPHARMACOLOGY.....	84
ALCOHOL AND SUBSTANCE ABUSE PSYCHOPHARMACOLOGY.....	85

PART IV – APPENDICES

APPENDIX A: Objective Assessment Measures: Rating Scales.....	86
APPENDIX B: List of Other Useful Books.....	95
APPENDIX C: List of Additional Journals.....	98
APPENDIX D: Books and Associations for Families of the Mentally Ill.....	100
APPENDIX E: Forms for Evaluation of Trainee, Clinical Supervisor, Teaching Faculty, and of Entire Course.....	102
APPENDIX F: Investigative Psychiatry Curriculum – Advanced Psychopharmacology Within the Training.....	116
APPENDIX G: Guidelines for Pharmacotherapy Follow Up Visits and Quality of Care.....	120
APPENDIX H: Psychopharmacology Algorithms.....	123
APPENDIX I: Psychopharmacology and the Internet.....	136
APPENDIX J: GeneMedRx Drug Interaction Software by Clinicians, For Clinicians.....	138
APPENDIX K: Reading List for ASCP Certification Exam.....	139

VOLUME II: LECTURE MODULES

OVERVIEW

INSTRUCTIONS FOR USE OF LECTURE MODULES.....	7
INSTRUCTIONS FOR USE OF AADPRT CD ON PEDAGOGY.....	8
ORGANIZATION OF LECTURES.....	9
Questions.....	9
LECTURING USING ANOTHER TEACHER’S SLIDES.....	10
USE OF CD ROMS.....	10
CONSULTATION – HELP IN USING THIS CURRICULUM.....	10

COURSES

Crash Course – David N. Osser (Editor)

<u>Antipsychotics</u>	101.1 – 101.18
▪ David N. Osser, M.D.	
<u>Medicine for Bipolar Disorder</u>	102.1 – 102.24
▪ Theo Manschreck, M.D., MPH, James W. Jefferson, M.D.	
<u>Antidepressants</u>	103.1 – 103.14
▪ David N. Osser, M.D.	
<u>Anti-Anxiety Agents</u>	104.1 – 104.11
▪ David N. Osser, M.D.	
<u>Drug-Drug Interactions 101</u>	105.1 – 105.19
▪ Jessica R. Oesterheld, M.D.	
<u>Therapeutic Alliance and Adherence</u>	106.1 – 106.18
▪ James M. Ellison, M.D., MPH	
<u>Art of Psychopharmacology</u>	107.1 – 107.3
▪ Ira D. Glick, M.D., Richard Balon, M.D.	

Basic Course

<u>Psychopharmacology In The Emergency Room</u>	201.1 – 201.20
▪ Michael D. Jibson, M.D.	
<u>Pharmacokinetics of Psychotropic Drugs</u>	202.1 – 202.31
▪ Terence A. Ketter, M.D.	
<u>Schizophrenia and Antipsychotic Medications (Two Hours)</u>	203.1 – 203.29
▪ Michael D. Jibson, M.D., Ira D. Glick, M.D.	
<u>Bipolar Disorders (Four Parts, Two Hours)</u>	204A.1 – 204D.23

▪ James W. Jefferson, M.D.	
<u>Bipolar Depression</u>	205.1 – 205.19
▪ Terence A. Ketter, M.D.	
<u>Antidepressant Pharmacotherapy</u>	206.1 – 206.21
▪ Charles DeBattista, M.D.	
<u>Treatment Resistant Depression</u>	207.1 – 207.16
▪ Charles DeBattista, M.D.	
<u>Electroconvulsive Therapy</u>	208.1 – 208.19
▪ Samuel O. Sostre, M.D., Charles H. Kellner, M.D., Max Fink, M.D.	
<u>Substance Abuse</u>	209.1 – 209.31
▪ Herbert Kleber, M.D.	
<u>Sleep Disorders</u>	210.1 – 210.31
▪ Daniel F. Kripke, M.D.	
<u>Psychopharmacology of Violence</u>	211.1 – 211.22
▪ Leslie Citrome, M.D., MPH	
<u>Traumatic Brain Injury</u>	212.1 – 212.25
▪ Jonathan M. Silver, M.D., Stuart C. Yudofsky, M.D., Robert Hales, M.D.	

Advanced Course

<u>Combining Pharmacotherapy and Psychotherapy</u>	301.A – 301.18
▪ Ira D. Glick, M.D.	
<u>Mood Disorders in Women of Child Bearing Age</u>	302.1 – 302.23
▪ Natalie Rasgon, M.D., Ph.D., Katherine E. Williams, M.D.	
<u>Atypical Depression</u>	303.1 – 303.15
▪ Jonathan W. Stewart, M.D., Donald Klein, M.D.	
<u>Panic Disorder</u>	304.1 – 304.34
▪ R. Bruce Lydiard, Ph.D., M.D.	
<u>Generalized Anxiety Disorder</u>	305.1 – 305.21
▪ R. Bruce Lydiard, Ph.D., M.D.	
<u>Social Anxiety Disorder/Social Phobia</u>	306.1 – 306.28
▪ R. Bruce Lydiard, Ph.D., M.D., James Ellison, M.D., MPH	
<u>Post-Traumatic Stress Disorder</u>	307.1 – 307.19
▪ Thomas A. Mellman, M.D.	
<u>Obsessive Compulsive Disorder</u>	308.1 – 308.23
▪ Wayne K. Goodman, M.D.	
<u>Personality Disorders</u>	309.1 – 309.29
▪ Larry J. Siever, M.D.	
<u>Eating Disorders</u>	310.1 – 314.14

- B. Timothy Walsh, M.D.
- Body Dysmorphic Disorder311.1 – 311.10
 - Katharine A. Phillips, M.D.
- Psychopharmacology and the HIV-Positive Patient.....312.1 – 312.15
 - Lawrence M. McGlynn, M.D.
- Psychopharmacology of Sexual Dysfunction313.1 – 313.14
 - R. Taylor Segraves, M.D.
- Sexual Dysfunction Associated With Psychiatric Disorders and Psychiatric Drugs314.1 – 314.19
 - R. Taylor Segraves, M.D.

VOLUME III: LECTURE MODULES (CONTINUED)

OVERVIEW

INSTRUCTIONS FOR USE OF LECTURE MODULES7

INSTRUCTIONS FOR USE OF AADPRT CD ON PEDAGOGY8

ORGANIZATION OF THE LECTURES9

Questions.....9

LECTURING USING ANOTHER TEACHER’S SLIDES10

USE OF CD ROMS10

CONSULTATION – HELP IN USING THIS CURRICULUM.....10

COURSES

Lectures Which Can Be Included In Any Course or May Be Optional

Neurobiology of Psychiatric Illness.....401.1 – 401.32

- Hugh Brent Solvason, Ph.D., M.D.

Evidence Based Medicine in Mental Health.....402.1 – 402.26

- James M. Ellison, M.D., MPH, Leslie Citrome, M.D., MPH

Herbal Psychopharmacology403.1 – 403.29

- James W. Jefferson, M.D.

Brain Stimulation Therapies for Treatment Resistant Depression.....404.1 – 404.16

- John P. O’Reardon, M.D.

Cross-Cultural Psychopharmacology.....405.1 – 405.29

- Edmond H. Pi, M.D., Weiguo Zhu, M.D., Ph.D.

Psychopharmacology in the Primary Care Setting406.1 – 406.32

- Roger G. Kathol, M.D.

Epidemiology and Treatment of Depression in Patients With Chronic Medical Illness407.1 – 407.17

- Wayne J. Katon, M.D., R. Bruce Lydiard, Ph.D., M.D., Robert N. Rubey, M.D.

Evaluating the Research Literature.....408.1 – 408.21

- Eric Peselow, M.D.

An Ethical Framework for Clinician/Industry Interactions.....409.1 – 409.16

- Michael D. Jibson, M.D.

Clinical Trials.....410

- John M. Kane, M.D.

Child and Adolescent Psychopharmacology

Teamwork: The Therapeutic Alliance in Pharmacotherapy with Children and Teenagers501.1 – 501.21

- Shashank V. Joshi, M.D, FAAP

Pediatric Psychopharmacology: General Principles502.1 – 502.14

- Shashank V. Joshi, M.D., FAAP, Kiki D. Chang, M.D.

Aggression in Youth: Treatment Approaches.....503.1 – 503.19

- Vishal Madaan, M.D., Jessica R. Oesterheld, M.D., Marissa Cummings, M.D.
Susan Kulovsky, D.O., Elizabeth B. Weller, M.D.

Pervasive Developmental Disorders504.1 – 504.20

- Andrés Martin, M.D., MPH, Jessica R. Oesterheld, M.D., John Bell, M.D.,
Vishal Madaan, M.D.

ADHD: Assessment and Treatment Across the Lifespan.....505.1 – 505.28

- Shashank V. Joshi, M.D., FAAP, Jessica R. Oesterheld, M.D.

Anxiety Disorders in Youth506.1 – 506.14

- Jessica R. Oesterheld, M.D., Andrés Martin, M.D., MPH,
Kimberly Walton, Ph.D., Vishal Madaan, M.D.

Childhood OCD507.1 – 507.12

- Vishal Madaan, M.D., Jessica R. Oesterheld, M.D., Gayathri Tadepalli, M.D.

Post-Traumatic Stress Disorder in Youth508.1 – 508.14

- Vishal Madaan, M.D., Jessica R. Oesterheld, M.D.,
Christopher J. Kratochvil, M.D.

Pediatric Depression509.1 – 509.14

- Cynthia R. Pfeffer, M.D.

The Use of Medications for Pediatric Bipolar Disorder510.1 – 510.24

- Kiki D. Chang, M.D.

Childhood Onset Schizophrenia: Evaluation and Treatment.....511.1 – 511.15

- Antonio V. Hardan, M.D., Vishal Madaan, M.D.

<u>Tourette's Disorder</u>	512.1 – 512.9
▪ Vishal Madaan, M.D., Christopher J. Kratochvil, M.D., Jessica R. Oesterheld, M.D.	

<u>Using and Teaching Evidence Based Medicine in Child Psychiatry</u>	513.1 – 513.10
▪ Vishal Madaan, M.D., Christopher J. Kratochvil, M.D.	

Geropsychiatry Psychopharmacology

<u>Dementia</u>	601.1 – 601.22
▪ Gary W. Small, James H. Ellison, M.D., MPH	

<u>Delirium</u>	602.1 – 602.28
▪ Barbara Kamholz, M.D.	

<u>Psychosis and Agitation in Dementia</u>	603.1 – 603.14
▪ Dilip V. Jeste, M.D.	

<u>Pharmacological Treatment of Aggression in Dementia</u>	604.1 – 604.11
▪ Howard H. Fenn, M.D.	

<u>Depression in the Elderly</u>	605.1 – 605.25
▪ Gary W. Small, M.D., James M. Ellison, M.D., MPH	

<u>Bipolar Disorders in Late Life</u>	606.1 – 606.15
▪ Robert C. Young, M.D., Benoit H. Mulsant, M.D.	

<u>Anxiety Disorders in the Elderly</u>	607.1 – 607.18
▪ Eric Lenze, M.D.	

<u>Schizophrenia and Aging</u>	608.1 – 608.16
▪ Dilip V. Jeste, M.D.	

<u>Alcohol and Sedative-Hypnotic Addiction in the Elderly</u>	609.1 – 609.16
▪ David W. Oslin, M.D.	

<u>Drug-Drug Interactions in the Elderly</u>	610.1 – 610.11
▪ Bruce G. Pollock, M.D., Ph.D.	

Alcohol and Substance Abuse Psychopharmacology

<u>Brain and Behavior: Substance Abuse</u>	701.1 – 701.2
▪ Charles P. O'Brien, M.D., Ph.D., Charles Dackis, M.D.	

<u>Addiction: A Disease of the Brain</u>	702.1 – 702.9
▪ Charles P. O'Brien, M.D., Ph.D.	

<u>Substance Abuse : The Nation's Number One Health Problem</u>	703.1 – 703.8
▪ James Cornish, M.D.	

<u>Marijuana</u>	704.1 – 704.7
▪ Daniel D. Langleben, M.D.	

<u>Stimulants</u>	705.1 – 705.14
▪ Charles Dackis, M.D.	
<u>Nicotine: A Drug of Abuse</u>	706.1 – 706.18
▪ Janet Audrain-McGovern, Ph.D.	
<u>Alcoholism</u>	707.1 – 707.12
▪ David W. Oslin, M.D.	
<u>Hallucinogenic Agents</u>	708.1 – 708.11
▪ Laura F. McNicholas, M.D., Ph.D.	
<u>Prescription Drug Abuse</u>	709.1 – 709.9
▪ Kyle M. Kampman, M.D.	
<u>Psychiatric Disorders and Psychotherapy of Substance Abuse</u>	710.1 – 710.10
▪ Robert M. Weinrieb, M.D.	
<u>Effects of Drugs on the Developing Brain: Pregnancy, Adolescence and Beyond</u>	711.1 – 711.10
▪ Marina Goldman, M.D.	
<u>Medical Complications of Substance Abuse</u>	712.1 – 712.23
▪ Phil Green, M.D.	